LLY250110P760000
- 0.08
- 0.000.00%
Eli Lilly and Co Newsroom
Novo Nordisk Stock Soars on New Weight-Loss Drug Results -- Barrons.com
Express News | Eli Lilly Shares Down 1.2% Premarket After Rival Novo Nordisk's Amycretin Obesity Drug Shows 22% Weight Loss in Early Trial
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $900
Allurion (ALUR.US) stock price surged violently; its new weight loss therapy can maintain muscle mass.
On Thursday, Allurion's stock price soared 80% in after-hours trading, following reports that the company plans to conduct clinical research combining its gastric balloon weight loss product with GLP-1 drugs.
Bank of America adjusts its preferred list for U.S. stocks: Booz Allen Hamilton Holding Corp (BAH.US), Datadog (DDOG.US) are included, while Eli Lilly and Co (LLY.US) has been removed.
Bank of America has adjusted its preferred list of US stocks, the 'US 1 List.'
Allurion Stock Soars 70% on Weight-loss Therapy Update
BofA Adds Booz Allen Hamilton and Datadog to Its US 1 List
Argus Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,020
This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly. -- Barrons.com
Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,115
Lilly Confirms Date and Conference Call for Fourth-quarter 2024 Financial Results and 2025 Financial Guidance Announcement
Why Is Eli Lilly and Company (LLY) Among the Best Large-Cap Value Stocks to Buy in 2025?
Beyond Big Tech: 20 Stocks to Ride the AI Trend
Top SA Quant-rated Medical Devices Stocks as Technicals Look Strong
Express News | Eli Lilly : Jefferies Raises Target Price to $1020 From $996
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
The speed of drug research and development has increased by ten times! Google states that the first AI-designed medication will enter testing by the end of the year.
Demis Hassabis, the founder of Google's drug development company, stated that traditional drug development usually takes 5 to 10 years, while with the help of AI technology, this process may be accelerated by 10 times. Former USA Treasury Secretary Summers once commented that AI's relationship with the Internet Plus-Related is similar to that of computers with calculators.